74%
de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor.
Debes considerar si comprendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
74%
de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor.
Debes considerar si comprendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Smith & Nephew PLC ADR
Cerrado
34.21 -0.32
Resumen
Variación precio
24h
Mínimo
34.14
Máximo
34.66
Ingresos | 35M 331M |
|---|---|
Ventas | 203M 3.2B |
P/B Media del Sector | 23.776 63.808 |
Rentabilidad por dividendo | 2.3 |
Margen de beneficios | 10.368 |
Empleados | 16,988 |
EBITDA | 133M 856M |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 Meses | +1.78% upside |
Capitalización Mercado | -668M 15B |
|---|---|
Apertura anterior | 34.53 |
Cierre anterior | 34.21 |
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Smith & Nephew PLC ADR Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Smith & Nephew PLC ADR previsión
Precio Objetivo
By TipRanks
1.78% repunte
Estimación a 12 Meses
Media 34.96 USD 1.78%
Máximo 35 USD
Mínimo 34.91 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Smith & Nephew PLC ADR Dist en los últimos 3 meses.
Finanzas
$
Acerca de Smith & Nephew PLC ADR
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Live chat